Stockscreener 앱 받기
0.6846
3.64%
0.0241
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportThrowback Trade - newsline.com
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PR Newswire
Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants - Stock Titan
Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan
Citius Oncology (CTOR) Edges Lower as Stock Holds Above Key SupportWave Equality - The Legal Advocate
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue PhaseBook Value Growth - thelegaladvocate.com
Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combi - GuruFocus
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation By Investing.com - Investing.com South Africa
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Citius Oncology Q1 2026 Earnings: Wide EPS Miss Highlights Pre-Revenue ChallengesManagement Guidance Update - newsline.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageNet Income Trends - The Legal Advocate
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
CTOR Q1 2026 Earnings: Deep Losses and Negative Surprise as Company Remains Pre-RevenueReturn On Equity - thelegaladvocate.com
CTOR Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider-than-Expected Loss; Stock Edges HigherOperating Margin Analysis - The Legal Advocate
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
Citius Pharmaceuticals Q2 2026 Earnings: Revenue Misses $1.7 Million - technotrenz.com
Citius Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Armistice Capital (CTOR) files 9.99% ownership disclosure - Stock Titan
TradingKey - TradingKey
Citius Oncology, Inc. (CTOR) Eps Diluted (TTM) - Zacks Investment Research
Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks
Citius Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan
What Citius Oncol (CTOR) is doing to protect its market share (On the Radar) 2026-05-08Insider Sentiment - newsline.com
1.70%
0.04%
자본화:
|
볼륨(24시간):